Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHCNASDAQ:MORNASDAQ:RAPPNASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Companies$6.27-3.2%$7.03$3.96▼$11.46$2.31B0.592.76 million shs1.34 million shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/ARAPPRapport Therapeutics$9.56-4.7%$12.42$6.43▼$29.74$348.90MN/A177,191 shs159,354 shsRYTMRhythm Pharmaceuticals$50.00-5.6%$55.22$35.17▼$68.58$3.16B2.3510,657 shs653,198 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Companies-3.39%-10.88%-15.74%-22.27%-39.76%MORMorphoSys0.00%0.00%0.00%0.00%+4.69%RAPPRapport Therapeutics-4.69%-4.88%-4.69%-46.11%+955,999,900.00%RYTMRhythm Pharmaceuticals-5.61%-5.50%-8.94%-10.68%+17.15%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHCBausch Health Companies3.9622 of 5 stars1.95.00.04.01.81.71.9MORMorphoSysN/AN/AN/AN/AN/AN/AN/AN/ARAPPRapport Therapeutics1.747 of 5 stars3.50.00.00.02.41.70.6RYTMRhythm Pharmaceuticals4.4233 of 5 stars4.53.00.04.32.50.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Companies 1.86Reduce$7.4218.38% UpsideMORMorphoSys 0.00N/AN/AN/ARAPPRapport Therapeutics 3.00Buy$35.00266.11% UpsideRYTMRhythm Pharmaceuticals 2.92Moderate Buy$69.4638.92% UpsideCurrent Analyst Ratings BreakdownLatest RAPP, BHC, RYTM, and MOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/24/2025RYTMRhythm PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.003/18/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$64.00 ➝ $66.003/7/2025RYTMRhythm PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$72.00 ➝ $72.003/5/2025RYTMRhythm PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$78.003/3/2025RYTMRhythm PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$69.00 ➝ $70.002/27/2025RYTMRhythm PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$80.00 ➝ $81.002/27/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.002/19/2025RYTMRhythm PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.002/6/2025BHCBausch Health CompaniesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$12.00 ➝ $8.001/30/2025BHCBausch Health CompaniesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$11.00 ➝ $10.001/2/2025RYTMRhythm PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.00(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Companies$9.63B0.24$6.66 per share0.94($0.89) per share-7.04MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17RAPPRapport TherapeuticsN/AN/AN/AN/AN/AN/ARYTMRhythm Pharmaceuticals$130.13M24.29N/AN/A$2.87 per share17.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Companies-$46M-$0.12N/A1.340.37-0.48%-577.82%5.24%4/30/2025 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/ARAPPRapport Therapeutics-$34.79M-$13.84N/AN/AN/AN/AN/AN/A6/2/2025 (Estimated)RYTMRhythm Pharmaceuticals-$184.68M-$4.35N/AN/AN/A-230.07%-367.36%-77.47%5/6/2025 (Estimated)Latest RAPP, BHC, RYTM, and MOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2025N/ABHCBausch Health Companies$1.46N/AN/AN/A$2.29 billionN/A2/26/2025Q4 2024RYTMRhythm Pharmaceuticals-$0.69-$0.72-$0.03-$0.72$38.48 million$41.83 million2/19/2025Q4 2024BHCBausch Health Companies$1.65$1.21-$0.44$0.25$2.51 billion$2.56 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CompaniesN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health CompaniesN/A0.860.62MORMorphoSys4.981.381.38RAPPRapport TherapeuticsN/A45.9145.91RYTMRhythm PharmaceuticalsN/A3.493.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Companies78.65%MORMorphoSys18.38%RAPPRapport TherapeuticsN/ARYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipBHCBausch Health Companies8.12%MORMorphoSys0.05%RAPPRapport TherapeuticsN/ARYTMRhythm Pharmaceuticals5.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Companies19,900367.93 million338.06 millionOptionableMORMorphoSys730150.62 million150.55 millionNot OptionableRAPPRapport TherapeuticsN/A36.50 millionN/AN/ARYTMRhythm Pharmaceuticals14063.22 million58.02 millionOptionableRAPP, BHC, RYTM, and MOR HeadlinesRecent News About These CompaniesRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Recommendation of "Moderate Buy" from BrokeragesMarch 30 at 4:20 AM | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Up 2.4% - What's Next?March 29, 2025 | marketbeat.comLoomis Sayles & Co. L P Sells 18,143 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)March 29, 2025 | marketbeat.comHC Wainwright Issues Negative Forecast for RYTM EarningsMarch 28, 2025 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Soleno Therapeutics (SLNO) and Rhythm Pharmaceuticals (RYTM)March 27, 2025 | markets.businessinsider.comQ1 EPS Forecast for Rhythm Pharmaceuticals Cut by AnalystMarch 27, 2025 | marketbeat.comQ2 Earnings Forecast for RYTM Issued By HC WainwrightMarch 27, 2025 | americanbankingnews.comQ2 Earnings Estimate for RYTM Issued By HC WainwrightMarch 26, 2025 | marketbeat.comCibc World Markets Corp Purchases New Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)March 26, 2025 | marketbeat.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells 344 Shares of StockMarch 25, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Receives "Buy" Rating from HC WainwrightMarch 25, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Given "Buy" Rating at HC WainwrightMarch 25, 2025 | americanbankingnews.com7RYTM : Analyst Expectations For Rhythm Pharmaceuticals&#...March 24, 2025 | benzinga.comConnor Clark & Lunn Investment Management Ltd. Buys New Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)March 24, 2025 | marketbeat.comRhythm Pharma gets orphan drug designation for its setmelanotide to treat hypothalamic obesity in JapanMarch 21, 2025 | pharmabiz.comRhythm Pharmaceuticals receives orphan drug status in JapanMarch 21, 2025 | investing.comRhythm Pharmaceuticals reacquires rights to Imcivree in China for $6.3MMarch 21, 2025 | markets.businessinsider.comIs Rhythm Pharmaceuticals (RYTM) a Worst High-Risk High-Reward Growth Stock to Buy?March 21, 2025 | msn.comRhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.March 20, 2025 | globenewswire.comRhythm Pharmaceuticals gets orphan drug designation for setmelanotide in JapanMarch 20, 2025 | markets.businessinsider.comYann Mazabraud Sells 75,000 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) StockMarch 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend Stock4 EV Stocks Facing Uncertainty—Which Ones Will Survive?By Thomas Hughes | March 7, 2025View 4 EV Stocks Facing Uncertainty—Which Ones Will Survive?4 Healthcare Stocks With Massive Gains—and More to ComeBy Sarah Horvath | March 29, 2025View 4 Healthcare Stocks With Massive Gains—and More to ComeD-Wave: Multiple Use Cases Emerge Following Quantum SupremacyBy Nathan Reiff | April 1, 2025View D-Wave: Multiple Use Cases Emerge Following Quantum SupremacyBroaden Your ETF Exposure With These 3 Overlooked FundsBy Nathan Reiff | March 6, 2025View Broaden Your ETF Exposure With These 3 Overlooked FundsRAPP, BHC, RYTM, and MOR Company DescriptionsBausch Health Companies NYSE:BHC$6.26 -0.21 (-3.17%) Closing price 04/1/2025 03:59 PM EasternExtended Trading$6.25 -0.01 (-0.22%) As of 04/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 03/31/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Rapport Therapeutics NASDAQ:RAPP$9.56 -0.47 (-4.69%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$9.56 0.00 (0.00%) As of 04/1/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.Rhythm Pharmaceuticals NASDAQ:RYTM$50.00 -2.97 (-5.61%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$50.74 +0.73 (+1.47%) As of 04/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Amprius Market Gets Amped Up on Growth Outlook 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
